SC Filed 2021-01-26 Event — SEC 0001193125-21-017733 →

Eidos Therapeutics, Inc. → BridgeBio Pharma, Inc. BBIO

Stake: — Shares: —

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

8 13D/G filings on this issuer

7 other filings besides this one

Filer Track Record

1 filings by this filer

0 other filings in the data moat

Short Interest · settle 2026-03-31

DTC 14.73

23,366,752 shares short · -0.6% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $581K

Point72 Asset Mgmt

Other 13D/G Filings on BridgeBio Pharma, Inc.

Filed	Form	Filer	Stake	Shares
2026-04-02	SCHEDULE 13D/A	VIKING GLOBAL INVESTORS LP	6.10%	11,842,434	view →
2025-07-01	SCHEDULE	VIKING GLOBAL INVESTORS LP	9.80%	18,602,920	view →
2025-05-14	SCHEDULE	KKR Genetic Disorder L.P.	7.00%	13,260,971	view →
2025-03-07	SCHEDULE	KKR Genetic Disorder L.P.	10.10%	19,260,971	view →
2025-01-31	SCHEDULE	VIKING GLOBAL INVESTORS LP	11.70%	22,055,375	view →
2023-07-20	SC	VIKING GLOBAL INVESTORS LP	—	—	view →
2020-06-01	SC	KKR Genetic Disorder L.P.	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. $1,500/mo. Pilots welcome.

Request a pilot →